LUMO - Earnings call transcript Q4 2020

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good afternoon, ladies and gentlemen, and welcome to the Lumos Pharma's Year-End 2020 Earnings Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session and instructions will follow at that time.

As a reminder, this conference call is being recorded. I will now turn the call over to Lisa Miller, Director of Investor Relations. Ms. ahead. go please Miller,

Lisa Miller

you. Thank

statements proceed materially remind with call would we expectations. actual laws. call, forward-looking uncertainties risks that could historical the that certain experience to cause These securities everyone federal this to under like subject statements to statements and differ Before results U.S. I are from made are present during or

X-K, The is forward-looking or could and update may contained the from page factors earnings made the information that to cause this we with actual the to be call of of filed concerning statements. call SEC. contained Investors our website. in the revise the obligation Form Information this release presented and on differ statements periodic which the forward-looking during afternoon no as speak issued reports Additional results company accessed the in only undertakes this hereof, company's date is our in

over Chairman; CEO, will today's on Kennedy, Chief me Joining Carl McKew Scientific Medical will discuss provide Officer; Officer. cash Hawkins guidance. a Officer; John Langren and Langren, I our will and call Chief the update, company's corporate therapeutic Gene with Rick. and outgoing update of Rick clinical and Rick Hawkins, the Operating financials Officer Financial Chief Chief to an call candidate, Gene review wrap President full trials, will and John are of new turn McKew, Carl up review our Kennedy will a call the year the XXXX now

Rick Hawkins

on therapeutic the initiation providing our Last year corporate the closed, transaction, significant recent a Phase for today's review good Pharma our of merger update OraGrowtHXXX the deficiency. novel the our the release candidate, our clinical to LUM-XXX, of completion achievement fourth put of for year-end and Lumos administered voucher a afternoon That we the orally standard of quarter of and and After and consists monetization Lumos hormone. in to pursue development in on where industry priority XXXX therapeutic foundation momentum we growth Thank of the with Pharma our with our hormone care growth continues XXXX period injections daily events Xb financials. disrupt marked on pediatric highlighting you clinical market strategy solid press thank evaluating of as potential joining And of you, us our for move Lisa. issued LUM-XXX trial activity forward. a Those PGHD the call. the

data anticipated Our Phase Xb with readout advance mid-XXXX. OraGrowtHXXX trial to continues

target who to up small been detail hormone current for initiate This hormone our of to trial trials. adults. safety OraGrowtHXXX is essentially LUM-XXX indications to our indications LUM-XXX the that later. eligible Kennedy of focusing LUM-XXX data XX and data In I in study plan subset from gather the we patients these a efforts expect growth to PGHD of alluded LUM-XXX clinical first our evaluate a and to currently and extension in our review children LUM-XXX exists in trial PGHD, program, will OraGrowtHXXX a we extension PGHD pulsatility long-term addition, replicate in current a with effects completed illustrate we shortly. trial and other efficacy we is growth for pipeline LUM-XXX with pharmacokinetic assess Gene will in This the other to. has product our just Also, more believe single-site potential pharmacodynamic trial, other We're today, introduced trial We on have which for once a the long-term in deficiency. approved.

IGF-X hormone from analysis publications studies recent growth peak data most using specific or useful of patients we to PEMs, moderate to of in LUM-XXX recombinant levels tests clinical growth trials. the LUM-XXX from peer-reviewed the LUM-XXX. PGHD respond identifying hormone in in as stimulation our baseline more of Journal or data in by approach earlier These human support serve likely are hormone the and pleased markers the Endocrine may enrichment levels rhGH These also predictive are demonstrate We growth Society. peer-reviewed data

We additional honored meeting, LUM-XXX to are late known Society also data Endocrine be as at also presenting the annual March. in ENDO,

diagnostic being data at secretagogues using recently in illustrates, lowest public our show our used dose the growth hormone and we LUM-XXX support the in hormone Xb McKew, to statistically standard patients hormone for bit details abstract LUM-XXX in John a These predictive agents. markers. higher distinction identified our COO will growth enrichment ENDO PGHD call. further to response Scientific Chief diagnose As these data elicits We our standard show that that the presented LUM-XXX between more growth are Phase trial, subset provide a at of efficacious deficiency. potential Officer, and data the on later believe than be by

voucher priority We the vaccine upon second FDA final tranche Ebola of had $XX Pharma. the review a in approval which received Pharma of the you in Lumos ownership, in payment of million and XXXX. resulting of $XX gross and XX% recall, issued September Lumos As to $XX was first a million January may million in

updated therapeutic our balance novel the strengthen of non-dilutive and strategy. our These to our licensure our pipeline estimated for for will support Langren, continue use more look XXXX. business provide business and another our will diseases. opportunity cash in We development acquisition for financials Carl through development candidate our CFO, guidance rare available to regarding further expand sheet funds to detail or discuss be

OraGrowtH disrupt management offer team over call our review fortunate I And the experienced from disease turn an potential to LUM-XXX, an diseases. So believe secretagogue, John rare to to advancement additional that current Expanding pipeline oral We mission. the offers John? the and our and suffering have potential LUM-XXX, that, we're we pipeline. rare will in hormone orally sheet of on potential to therapies secretagogue, published administered recently to opportunity our injectable reach growth the balance trials our solid to where only this PGHD market of expansion execute growth excited the hormone an the year would about and data. consist And a treatments. the individuals with with are PGHD ahead and of

John McKew

Thank you, Rick.

stated, LUM-XXX to we in PGHD to are Rick trials As OraGrowtH validate patients. our excited advance

also pleased the PGHD to recent the care. are compared of the We presentation showing in and potential action LUM-XXX publications peer-reviewed ENDO LUM-XXX mechanism about novel of as data and standard efficacy upcoming of of of

from and its option of preferred believe for Given hormone hormone deficiency. that depends treatment natural on offer endocrine suffering its of XX% we action delivery a oral LUM-XXX approximately may axis, growth the mechanism that growth children

be for reminder, can to absent of other restore hormone a secretion to long-acting growth. consist The with growth hormone defined deficiency the by of of growth bolus in deficiency derivative development hormone or gland. from standard low growth the of delivery therapeutics growth children and a current of care hormone As pituitary a

of the hypothalamus IGF-X needed LUM-XXX loops All other to of therapies pathway. endocrine are feedback to occur secretagogue at preserved and balance in a act is growth growth the injection body. feedback hormone the but same outside receptors not should body's that feedback natural growth natural a acts these LUM-XXX, instead body's and Utilizing to regulate if stimulate that hormone on naturally. is administered endogenous growth the levels the same of naturally loop be and to the this within release the selectively mechanism pathway help enable endocrine subject intervals occurring ability hand, in the to hormone release and the pituitary on IGF-X body's by mechanisms. endocrine acts hormone

must the have Given as diminished LUM-XXX described, endogenous to nature pituitary functioning the a – a able of axis. individuals from activity molecule just benefit

IGF-X identified of or Lumos why insufficient produce nanograms total growth or height. amounts For illustrate this are Based to patient group Pharma likely to greater but of in X the of a specific moderate a than to a LUM-XXX mil therapy, the a of per these identify Merck to and benefit of characteristic demonstrate the patient are with than the the dose and peak that of enrichment trial. mil PGHD in assigned the our or from the population OraGrowtHXXX markers this data. clinical determination in PEM included treatment is that for likely Predictive of discussions. moderate to who in growth PGHD equal data, Growth greater their analysis a of LUM-XXX obtain PEMs of prior Journal this of reason, is of we normal iterative in to the XX% cutoffs. These peer-reviewed which patients population. to able single a paper on hormone PEM level analysis receiver targeting level the predictive respond safety referred LUM-XXX and hormone after naturally prior LUM-XXX PGHD baseline Described our are represents data Children per some approximately PEMs have nanograms population support recently specific adult analysis growth XX PEMs PGHD curve paper using is XXX in Marker Oral that data Hormone study Secretagogue each Enrichment enabled from detail Development The operator entitled published and the of of Society strategy. arm to analysis Deficiency relevant in study Hormone The is Endocrine filtering analysis the of Growth Also data children we ROC

hormone analysis study and and to growth This growth in were study. pediatric assessment were marker in sites database, hormone the with LUM-XXX of GeNeSIS that given the Secretagogue growth care in failure. Corroboration PGHD size main our Between to and purpose conducted IGF-X From of for human with Journal paper enrichment growth of source at the available data an hormone hormone and was rhGH exercise treatment twofold: X effectiveness Lilly's of rhGH GeNeSIS was were Society in analysis. This of described of use growth stimulated of Markers scope, hormone respond Baseline Eli and hormone. collected standard safety the served published XXXX. XXXX mining to in database. of naive-to-treatment stimulation database, determine The XX-month baseline between XXX patients they the a The observational growth prospective Growth predictive recombinant with most to entitled Hormone markers with the the legacy to human XX the data children whose and Velocity growth likely the additional provides Lilly to were Treatment GeNeSIS idiopathic enrichment paper likely patients in prepubertal most to respond GHD Children support paper second a deficiency. program Oral recombinant objective velocity IGF-X peak to in idiopathic administered, as in for more research than of evidence tests its XXX for those described Endocrine treatment Predictive investigate Height Phase first, predictors Enrichment children describes for data The versus real-world was and independent publication. external mining open-label those countries predictive evaluate useful deficiency GeNeSIS height

idiopathic the range that as deficiency correlate with Secondly, of XX as subsets deficient isolated growth XX% of of of represent population be treatment. how deficiency severely term XXX growth deficient PGHD better while children database or Using in the were PGHD moderately diagnosed were PEM severely the hormone identified XX% the of XXX cutoffs above, or and growth what positive. exists the population growth hormone idiopathic within or diagnosis XX% to we PEM were the GeNeSIS hormone to hormone patients, respond would noted approximately hormone of or moderately understand a deficient to categorized of XX% growth with determined deficient. the XXX the Of XX% database total of GHD, who patients

height the the had year levels IGF-X arrived Further and group, lower PEM Additionally, lower treatment catch-up deficient those growth moderate – catch-up of and velocity groups showed after in using the velocity with after because minus levels, PEM-positive height higher deviation recombinant of hormone height these with SDS analysis as baseline differ that hormone baseline same during severely two the X.X height at standard IGF-X of companion groups group, velocity their prior as after these with baseline hormone rhGH, levels both growing higher in stimulated moderate Merck on or hormone. treatment. saw analysis growth study segment growth stimulated change and rhGH stimulated X.XX. height those on significantly predictors showed and of lower greatest levels, levels severe IGF-X markers minus the XX growth significantly height score, year. groups cutoffs whereas per by and growth hormone to one the height evidenced treatment enrichment chose at We scores the rates, human velocity with were independent growth for recombinant regression X.X human of peers predictive multiple one they moderate months compared centimeters severe Despite at treatment place year different average treatment and

outgoing Finally, Elicits abstract standard of in than later presented patients from data supports values. Hormone in presentation other Growth with be that the hormone the hormone strategy to for at is Greater IGF-X our March peak with LUM-XXX diagnose Deficiency distinguishes PGHD Medical Officer, data The data data secretagogues to accepted update Pediatric We PGHD. community call with turn suggesting Growth Response The a difference those in at Hormone and Secretagogues to secretion development growth the traditionally upon secretagogues. clinical our to its look diagnosed LUM-XXX ENDO Standard baseline I support Growth now forward entitled LUM-XXX provide analysis that LUM-XXX on growth strongly among GH full value stimulation used was our unique PGHD. data higher deficiency between these Gene? growth believe investment to trials. ability higher presenting even in will the of Kennedy, welcome hormone Cmax in over children that And ENDO the values Chief Gene We discussion greater an produce at time. in Hormone the to

Gene Kennedy

PEM review three will approximately to the OraGrowtHXXX trial We specifics our a quarter, some John. last in on levels into of PGHD predictive Xb by a standard as those of PK/PD equal trial trial this milliliter, care of dose randomized positive, trial continues Thanks, peak review, initiated be PGHD our of XX shortly. cutoffs trial baseline Phase our arm or or LUM-XXX therapy. provide to a be one evaluated I PGHD per per of IGF-X OraGrowtHXXX marker study. will To growth X nanograms than milliliter advance. global growth initiated to hormone randomized take multisite enrichment a Xb and more determined greater patients hormone in level the now time involving greater few than Phase our comparator Only injectable to XX nanograms to is and OraGrowtHXXX and trial be patients

potential administering Merck LUM-XXX height per classification study Xb LUM-XXX statistical hormone. are the for PK/PD only recombinant in Phase patients healthy approximately PEM-positive will mentioned of adults cover from LUM-XXX hormone. difference data our two predictive velocity optimal a These in and adults strategy selecting data to the likely responders LUM-XXX those PK/PD average increasing no for study concentrations Phase X.X per to assure kg will levels The chosen versus the that PGHD that LUM-XXX X.X were children, milligrams, consistent PGHD PGHD study potential classification mg equivalent Xb X.X PEM trial our three full six The Each result The approximately The showed administered X/X PEM Phase be healthy way of as Xb main kg higher Merck plasma that a based that XXX response enrolling with annualized as our up in the well confirm of for is in showed for clinical a kilogram Xb trial for of and dosed greater Phase X.X, repeatability X.X X the height human open John of the trial. be to in milligrams in samples per healthy for per will of patients with X.X the repeatable patients dose utility efficacy patients growth the kilogram during and Phase of dose determine in dosed adults. this on for milligrams dose suggest the of registration supporting range and as prospectively is chosen growth hormone to During of in curve. screening in The of study trial the months prior three for apart. showed participant growth over week The is PEM sets randomization. with study, dose have currently. growth hormone evaluated laboratory this in study. doses and with PGHD the the Dosing velocity patients our marker objectives secretion mg the in and pharmacodynamic doses potential key outcome of study measure. enrichment drawn

about oral received strong feedback for for have therapy PGHD. potential positive the We an

sites and We have of our with others prior and clinical patients enrollment Russia identified sites in Israel trials in all their readout. in history increases alignment additional in based This experienced Ukraine, interested study. our PGHD the on mid-XXXX trials enhance to standards. in data our clinical in participating anticipated the confidence process and should These our selected and ability enrolling conduct were

amplify hormone. this hormone. hormone While efficacy and LUM-XXX a XX intended The milligrams This pulsatile the X.X believe in pulsatile illustrate growth sample OraGrowtHXXX is patients X.X this XX- purpose measured further body to a pulsatile at conduct types of then ultradian and of six the that is a every continuous of OraGrowtHXXX growth concurrent for growth their is specialized two growth will focus to of six important second on augment clinical of end ability approximately illustrate same this At to children ongoing, plan with end with these perform to maintains trial natural We PGHD. of pulsatile levels. pulses confirm levels data the pulsatility assessment PGHD. trial of to growth nature, pulsatile the baseline XX minutes Lumos the PGHD the the in produces hormone hormone in and mechanism with with a peaks greater for and monitoring at kilogram, regulatory the Phase with secretion hormone center hormone. period the will hour hormone of frequent hour of months. they to doses, ongoing Children this with again than of data that any Prior delivery order these preclinical amplifying trial as exposure secretion LUM-XXX way amplification replicate ability amount per adults of growth different have of secretion in growth is run natural points pulsatile initiate of study supportive pharmacodynamic growth peaks more over the the in XX-hour action a required these of to data start of on have stimulates LUM-XXX will for will single months, and We the pediatric LUM-XXX IGF-X amplifying children over with levels collection to growth mechanism, of LUM-XXX's hormone trial trials. efforts. in secretion XX data ultimately LUM-XXX and filings given XX in in Once period. future providing expects initiated, is commercial illustrate growth trial marketing study in secretion. the trial of goal in The shortly. hormone a our to natural OraGrowtHXXX Xb XX of parallel secretion in the The the to

at We fire San a Chile. Santiago, Arriaran This site OraGrowtHXXX the trial. for have in Hospital the planned of the Borja been advised clinical is location

was involved directly clinic investigator's the not Our fire. in

the fire the access start. to hospital site our might the trial impact of limited However, delay the as assesses

initiate in OraGrowtHXXX QX QX XXXX. While this expected trial initiation occur to we of had in the we of XXXX, originally anticipate now the trial of to

do trial is the regulatory our not pathway critical LUM-XXX, fire line. will and any previously for not have this of the cause delays stated, we to anticipate we time on As approval

sites to the to conduct work exploring to site our manner. event in we advance the in We that timely local unable the a and proceed are trial also is trial, the alternate original continue to partners with

The be month open-label, a the those the such for PGHD. prescribed patients also LUM-XXX. of introducing dose growth six are will of be or either an OraGrowtHXXX the enrollment trial. OraGrowtHXXX extension this completed who as hormone in their Eligible administered the trial have of primary trials. safety will will OraGrowtHXXX trial LUM-XXX trial multicenter, those recombinant have trial prior LUM-XXX OraGrowtHXXX This long-term in long-term preceding upon who human to in evaluate study studies study We in and LUM-XXX the completed objective treatment be

this In to effects PK/PD long-term assess LUM-XXX addition, study growth will the treatment. in and response outcomes

is as our indications. we that these believe therapy concurrent for potentially serve evaluate which LUM-XXX to plan hormone growth other Finally, to may a OraGrowtH platform indications we from in Pending discussed, approved. recombinant LUM-XXX other trials results applicable just

call opportunities pipeline continue Beyond suffering Carl? actively XXXX and pursue to LUM-XXX, we ability financial results I from our to Langren, order disease license development therapies provide discuss and cash to for other diseases. rare the business to or forecast will for our Carl turn in rare provide innovative assets to our over to CFO, the XXXX. those now year-end acquire a expand to

Carl Langren

XXXX $XX.X was in Thank This not and of the final million. million proceeds include January. you, from PRV, in cash $XX balance ended received Gene. year-end of We does sale which with our the cash equivalents

For XXXX, million $X to we anticipate average quarterly cash use million. of approximately $X

period cash of We through plus expansion sale OraGrowtHXXX the contribute to readout supporting that rare financial and we $X.X the data details a put net out XX, net loss December the refer reported the for Please reported results. from XXXX, press trials the funds for expect non-dilutive the to our the and balance a our same additional company's compared million pipeline. $X.X will release XXXX. on We this loss OraGrowtHXXX of the support also in of our our year disease to of PRV ended million afternoon for operations

of Looking hope Roth in participating you Wainwright this the H.C. to we conferences many with Oppenheimer, month. & speak ahead, investor

looking annual We of data forward we in you meeting March. are ENDO late with once all also the to at present our speaking

Rick? I Now like the for open call to over before would Rick turn to questions. up back we

Rick Hawkins

Carl. you, Thank

the offer discussed Lumos Gene team tremendously and Gene with I before as first by NewLink programs also about few Pharma's a joined say listed merger some and company to about want Gene merger diseases. Genetics, our transition Chief which publicly rare of Medical Kennedy. where Medical Chief us way focused he was management through joined closing on XXXX words an he a remarks Pharma above, helped Officer. Lumos so outgoing here Officer, to our oncology-focused I And served in our company

will While Lumos to Gene, field. for Pharma now want for and we returning you thank all in we as your held joins he next company he a him that oncology the venture. be would roots his you to stay, wish privately to to best have in your in service loved

Gene Kennedy

Thanks, say your mean Rick, have enjoyed with for thoroughly kind the I words. really Lumos to that I've I entire working team.

said, be the I and returning you As by Lumos highly the and confident team as in be from am to really markers predictive to clinical with my potential expands on the that ability also in place. team's purview. the to the program roots. in identified and efficacious hope all PGHD pulling I'm for to PGHD your already LUM-XXX advances team will population keep success its touch for beyond distance plan and LUM-XXX the and the in of a enrichment I in in execute ability watching

Rick Hawkins

questions. continuing to believe to potential Operator? to that, our with footing will forward market. call strategy clinical we in and you can for at recently trials Gene. as We as And And our that our to we trial. for our PGHD about look And data to we're well, on forward PK/PD our LUM-XXX published tell, and to excited trials execute the are we pleased on disrupt solid confirm will open ENDO. provide about the We're updates OraGrowtHXXX of progress. look Thanks, and PGHD advance OraGrowtH upcoming the presentation financial initiation the

Operator

Cantor comes First question the of Duncan Instructions] from line Fitzgerald. from Charles [Operator

You now live. are

Charles Duncan

early Thanks of enrollment. I the terms Okay. question all and you, taking end period Actually, rate patient progress XXX I to quarter had for Thank pretty enrollment dosing our And XXX Rick the a imagine about congrats the on of anticipate questions, trial pace would on at with the or second month can But talk that on you and this XXX, time? first be team. to the in thus trial. the year. it's of you and therefore days far. this six extension start the able period, open-label by through at the being trial, screen of failure the the

Rick Hawkins

Chaz, question. a Well, that's good

on we're really the But progressing that nicely. given entry guidance study. haven't We to into any say yet suffice

all us We world there as online sites a meet having And quick help of but in KOLs XXXX. our out, are in goals coming that part of experienced pointed some readout haven't new in another of we Gene initiated our XXXX, order. believe the with investigators they're year and pretty will sites,

Charles Duncan

about And or point? this strategy anything Okay. that screen failure at PEM at all

Rick Hawkins

I think the address early to too really game in it's that.

I is probably parallel over John the that found think that the of rate going what failure publications just went deal gives us great of confidence screen in a we that in database.

think that I report can, that's as – but we'll as we on soon So to you data.

Charles Duncan

patients terms moderate compare growth in the that height at the of patient population it, looking you you that. a annualized lot versus more population? and height would you there be, one mentioned numbers then appreciate What said might are over so just And could think a I I of, recombinant patient follow-up. call and John Okay. XX% of I would said quickly, sorry if missed the that and but positive moderate, estimates at. expect for And that kind patient previous you of versus, what XX% could over say, in predictive met kind human of average severely level of that go again? I velocity? terms population marker so course And guess in velocity I'm looking hormone are that impacted around an expect wondering, or enrichment of you what this, for out more that you you're contrast math example,

John McKew

to Happy that, Chaz. answer

be start responsive. So the we'll that with the numbers population for patient of the estimate could

standard database are groups, else PEM that translated help in the them GeNeSIS and the cutoffs the taken so we've everybody sort that more can essentially, us them our of severe. kind patients and to use test two group So stim use same diagnosis PEM-positive into we and the

diagnosis. the look of database focusing the the set those Of of up large when officially children deficient And criteria kids deficiency that positive. hormone we're growth data at makes so that's the the you GeNeSIS, PEM with XX% And our are hormone on meet XX% children. in idiopathic GeNeSIS XX%, growth termed

be regions X.XX a could X category. more estimate multiplying our just the large about by to from number make just that set. the XX% the and gets of responsive molecule Phase I think this could a derived this really And more So because is trial running. X.XX very we trial than confident from you feel the number because data into much was We several XXX real-world of it about PEM-positive to fit would it's that

confident about we're So that number.

velocity second see. The question is we the about that height

group set, GeNeSIS that centimeters per if on in that showed XX-month the growth human you group data it's our X.X is PEM hormone a about in analysis year. And selected an So cutoffs many the clear rates include recombinant very of first that's growth with that growth, our patients potential that are would much from trial, at months. more a severe we in higher out more severe six population who growth. have grow filter the simply And that of would those includes faster rate because kids broader

going a for we're data forward. population in So is that per trial centimeters look like good going growth to going we're our a indication of have the trial what would same pretty that to that isolate X.X year XX-month in

Charles Duncan

pop with wouldn't more you want this patient size sample? or But compare to severe or apples-to-oranges sample

John McKew

Yes.

kids. our how year. they're centimeters X.X statistically the you think more, severe going it different essentially, the severe more to moderate per kids kids. significantly to I exactly analysis, In GeNeSIS than Depends grow right? grow are But was more define going

they're and very different different So populations.

Charles Duncan

Or and you understand for response of in velocity? believe six or be a of Does authorities rate implications question. think or of going prescribers height patients the in Okay. will months? terms And that's entire reimbursement to conduct not study issue? terms annualized the any this keeping do have on an that the Do last you that

John McKew

that to most grow And less hormone a on in So they that And understand the not much most using the prescribing that different have They're they're the we're for molecule. growth severely the understand months. right? for are our I clinicians set kids think I to human hormone growth grow will growth that tools of grow less they deficient they're grow. going kids molecule, the they whether recombinant that hormone going to how given select or patients moderate understand will first our to will think – going it's expectations most the select six once those deficiency, just

Charles Duncan

makes It taking Thanks my for questions. sense.

Operator

Next Ed one from is H.C. on White the queue Wainwright.

live. now are You

Ed White

see, be sites the for you think of by and are enroll clear you the up patients? us then? have Poland, the enrollment Israel. currently had the will at Should of Zealand. that other you to areas, I expect we you're previously expecting just patients now to Ukraine any these in running enrolling XX U.S., end the And to said would Can So be year? of sites, and give the and all New number on idea interest what they Australia Or say, sites Russia by in and

Rick Hawkins

Yes. that? Gene, take to you want do

Gene Kennedy

aren't shortly will year, the Well, slightly few – The of By have be expected in no, thereafter. right the weeks many definitely. certainly. we end again, and the then the coming up of we to running. end I the year. our international Yes, sites that sites, be next – But month think are up before of them and up to U.S. the

these – while. today So starting and saying. that understand are in countries – the been we're This I'm what this aren't today. you been if for sites announcing our we're work we've intentions has – we open preparing not It's these to a

sites soon. pretty to able all expect to these we contribute be So

Ed White

about give study a thinking on moving open how that And study you. that Thank OraGrowtHXXX before Okay. affected you to to fire, was site or different the then the long will location? start by the you

Rick Hawkins

Gene?

Gene Kennedy

the finished I It they're be likely – certainly. back it's mean hospital. that a we we're report thinking, exploring Yes, have major large consequences running pediatric I is of Santiago, Chile. up the a in they'll of and But to very they're clinics are. we optimistic soon. part where options. be obviously And mean other their already portion of population the in the had some with building, but it's serves repairs the parts

proceeds guidance we're to beyond So then obviously, our going into QX, If short it to I consider this be think all optimistic options. is other we'll have that delay. a

Rick Hawkins

here going that what, is sure about. though all confident a viable no is matter want have site That's business And going and a that plan. to it's our the make hedge even forward, what to bets this to sound we I we Ed, think backup procedure we're – be site

Ed White

the puberty? to patients of are you. continue – a and last after eligible Once the just these end long patients would you through how are completed that. following? is enrolled, time thank do Or would short they Thank until follow them my is you. them I XXX perhaps you study, question be to XXX. Okay, And extension then those just mean to expect on continue

Rick Hawkins

ahead, Go Gene.

Gene Kennedy

and beyond sort physicians to our I follow that beneficial. believe those would as to would But OraGrowtHXXX intention the be be the live and end the to therapies kids to no, families as That's trials the or nutshell. long believe of the in them a we their XXX answer expected OraGrowtHXXX allow it's and clearly. access Yes. of mean

Ed White

taking questions. Okay. Thank you for my

Operator

from Next one on Yang Eun the Jefferies. line is

now live. are You

Unidentified Analyst

taking [ph] This Min our Eun. Thanks is Soo for Jang for on question.

And then based an number plan first study just just question Thank do is on to Xb. based PK/PD I'm patients design? to of the second just on trial the look question of data, first expect the you. to Phase interim and the study Xb relevant Phase but question, wondering is the Our that. you kind adjust do the maybe on you if of

Rick Hawkins

take John, do first? John, think… you want I to that

John McKew

answer that. Yes. I'm happy to

So data think for the an at that Xb Phase we look be don't will necessary XXX trial. interim

more trial. the with trial. going in XXX think also along about design any of PK/PD really release. study way it's about study to pulsatile separate We of go nature in parallel results not XXX And the that the influence to PK/PD do the going be that's understanding the is study The a will

Unidentified Analyst

presented I before? been ENDO presentation. my see. question this sure. to And Just the data wanted last XXXX Has make is

John McKew

presented has data abstract That's not the in of specific poster. that the No. No, been previously.

Rick Hawkins

be would And more Eun, back we than circle go pleased you to with to over.

Unidentified Analyst

Thank be That’s you. Yes. great.

Operator

the one from Kaminski JonesTrading. is Lina on line Next

now are live. You

Lina Kaminski

me guys, you for Hi squeezing in. thank

maybe for So John. I one guess this

about the So talked recent you publication.

appreciate I that. So really

maybe confidence gives the kind trying difference between maybe you have standard X. growth versus bit X XXX of specifically marker what I'm for ongoing can you the also strategy. of of elaborate further a the bit a the follow-up. a to LUM-XXX? stimulation little then the enrichment the test And I LUM-XXX, the So trial little guess on the predictive and the just towards support stimulation between nanogram per understand test I relationship ml And and hormone then the kind

Rick Hawkins

John?

John McKew

Yes.

So let first. take the me last one

in the correlation standard results see in stim diagnostic LUM-XXX X, the test and the Table between manuscript, you'll Bright stim So results. test a

five the correlate tests a sets. data that's have then a the test is receiver values than those stim be. their in standard And of on and this So to characteristic with the data we're stim equal applied what than to test. patient, standard greater curve right? PEM response stim essentially in the And we LUM-XXX analysis GeNeSIS ran greater And that we same similar operator able the up different patients to then the two because set none data taken we with to that's And diagnostic test. that have correlated database, or stim simply those they come would

manuscript. two papers between in that's the the those So of connection Bright X Table

our do of about feel potential So publications success. in we terms how us make these feel – more confident two how do

cutoffs, in all of of the showing the do the the is these parameters. we very in find deeply to the to evident Bright the very about first, data we've first, the very and in I how the approach but I supports right approach think how we results that one think different breakpoints is glory, that we thought that. way important IGF-X growth We right both been And manuscript hormone quite PEMs and it's our scientific the to stimulation two worked recombinant were hard time, And the values its a for out derive – independent think human speak. for so in now rationale manuscript I just some – growth the this values hormone. of analysis in think get patient and to took growth population, cutoffs scientific on took it baseline predictors was I shown very to Blum clearly the

use moderate going with So markers We what then do put help a or going as them category receptor. child able know And more in stimulate a out these they're at group the turn severe this partially to Because that severe to a to PEM-positive respond respond. a that a is the rates. we're if independent functioning to to markers continuing is some really category show to to be secretagogue, release able it PEM less how going group, we has to LUM-XXX they to can they have be to patients into to that means good want predict our of make can right? different the that to them and versus product, they're to group and because likely grow. we are that hormone, very moderate with grow we is physiology growth essentially, combine moderate predictors the be growth, group to separate or that axis And by

from. So of I derive question, to aspect made we hope we that It that supports that choices cutoffs like the Lina. publication. answers your

Lina Kaminski

Got it.

your the about the kind And and have population. you're on guess thinking I patient of That's is really Yes. more I last question just strategy helpful. Okay. how

you about enrolling do you're conducting patients. think previously population? are that? you So maybe think treated switch thinking you were of benefit that further But patients – they how obviously, And growth a naive that do you thinking might hormone, study with now from Maybe are LUM-XXX? like

Rick Hawkins

a has good the study of at to on. Lina, into Most then this to that anyone the go will certainly that has around question, dose it's goal type I a think and time. And and front is is of after that in to over. we for eventually in this get in objective focus this get switch study, And right to a will trial space registration timing us we efforts who important product study.

think feel John, to that being we would on there's whether would the think, and part patients I scientifically, part drug whether the on treatment gain those maybe switch I our prediction of question, also her benefit. – any second long-term our

John McKew

patient of longer stays hormones. a the in months' So growth that therapy, is I same the think think I known not their on is – switch exploring in with growth those a XX what the human patients recombinant is maintained, growth there growth history long-acting to first it's level is some see but those hormone of you six And frame. of

recombinant able to while take expect then patient would expect the their a meet for daily on criteria would and they put PEM would respond our out I they So of hormone, that that on kind a injectable be treatment. human growth you would Then wash if they them them drug. to – you from

the But somebody than our been And from criteria, you our to hormone going a naive molecule You're molecule. if that's a recombinant that for understand on. right? rate these respond again kids on to to think our switch to molecule will important able yes, patients, at that. different put It's I years growth any growth do who's that slightly will five get meets you same or with they patient be human

Rick Hawkins

questions? any Operator, other

Operator

Yes, do Sandler. a we have Yasmeen question from from Piper Rahimi

live. now are You

Yasmeen Rahimi

you, team. Thank

working wishes say and I you, best thank Gene. before question, luck next just with adventure. team a you my pleasure I your to First, the It's want ask you, in been my of

recombinant around than certain pipeline have what groups highlight an I one therefore, a hormone would require, the to set off the study, XXX maybe of The The there's two second questions. rather not I and study. size to of growth then I LUM-XXX. a third patients was me start regulators, like is have So discussing just that of it's open-label with requirement the meeting the have reason safety running the for And there is Maybe a certain set is to one question you. of just wonderful doses question. Maybe extension? open-label is of a with you first – working been the data

Rick Hawkins

start? John, to do you want

John McKew

Sorry.

the so XXX about I trial. I think, – you asked, think

comparator growth why XXX, asked hormone You Is said in trial. the that trial. correct? recombinant that's You there think, human that isn't a I

Yasmeen Rahimi

Yes, that's questions. one of the Yes.

John McKew

Yes.

with kids at could wanted There's working case, human really to a in site enough single And a there. or or – Chile. LUM-XXX kids that study us we're of different background historical site growth of sure two doses data we a amount single on I think the into on So explore that are on in recombinant that enable that recruit to make decent we patients to growth hormone.

also growth of PK We hormone like the human in what looks kids, right. recombinant know

at So recombinant look the growth trial. that thing in that hormone the effect same going as the we're of to effect human is PK PD

going is right, PK very in well to hormone that we goes the is given XX clearly because and dose, curve and So away, be a it's growth that the being is of bolus so what at released know night within characterized hours for single or look eight the the difference comparator.

focus sense? didn't many that as kids make rather arms. necessary, that we enrolling So would we and think it part as on we treatment can Does was in our

Yasmeen Rahimi

that's No, of is needed And that Yes. size for the then helpful. to regards the open-label in study submission?

John McKew

Yes.

as open-label from X to puberty an long mentioned XXX that's the trial, that or There's from into there So Xb Phase to upcoming from any go of we can. possible. trials long-term kids as that data as on it We earlier like we potential kids as while Phase get we're right? study, – – Gene continuing study. want was our who's much on in for in kid interested I the mean study trial the to any enroll that, going

benefits to to from stay their have on a into there. data treatment. we'll certainly opportunity So We don't collect be that as lot and number how But inclusive the able like like should who Anybody fixed of have of enjoying we'd a many can. we'd be to mind have. to we in switch is as LUM-XXX

Yasmeen Rahimi

safety So prompted make extension. needed the wanted sure or there that I data of open-label is clear requirement that's, no that additional safety just to sorry,

John McKew

get working extension like just It to in multiple pretty of makes You patients. therapeutic enable for a these No. them, experience they right? to of is But it common No, is sense years build good it for they them to sense, take kids also if requirement the disease when have a and open-label most upon it. the on it. feel the If want therapy us – of – to filing. NDA lot are studies, makes good the do continue no to all to who database there's I mean you in is rare an of

Yasmeen Rahimi

Maybe And for quarter the ahead in is or pipeline you the can to where on the and then expect licensing LUM-XXX this in-licensing the Thank you expansion see pipeline one. and/or are we the you could Great. your comment two – with on clarity. whether of happening question of opportunities. next over discussions whether be

be if little a So you more give it helpful. just would granularity, bit could us

Rick Hawkins

minute we question. we the will. And let Yes. you Also, it's can a good know,

taking cautious and guidance find But broader as right the want to little but assets of asset we you, it's pleased years now, where give We And And say, experience, we tell think number to yet to are haven't it's the or I process, endocrine our given for throw too veteran and right guidance Obviously, outside – being by the we would an are any one. we we look can that's possibly as this in led a time the whole like with over can stay to any – we're company. I opportunities, this let's right to other a industry compounds of it's Aaron with of at endocrine. I'm space, robust now. and XX willing to on a net Schuchart. but early

Yasmeen Rahimi

you, Thank color. Thanks Rick. the for

Operator

Next one line on Roth the Piros Elemer from Partners. is Capital

now live. You are

Elemer Piros

and least growth, would therapy it degree Coming allowing populations, regimen? previously thought of the questions. daily is for therefore, these Yes. sort their to make LUM-XXX growth for there using of also oral that suddenly, that might catch is couple a treatment-experienced Hello. that in high where under is now noncompliance back there sense, pill, an at you subpar there theoretically, and of available, injections oral a if children of Thank with up experiment

Rick Hawkins

John?

John McKew

good think I And Yes. a point. that's very

there do parents the think very as You'll that general, kids to tends – A – so The them. more note tend clinical because just their times go a trial compliant growth to most interested that especially up In it their be started seem after compliance. But most out because years opportunity kids – in I lot of in that's the peak having be a instead I world, to after real ones the I in do you susceptible that they to agree. which sign the true. there's they big the do and on five quite drug control start they of in their therapy. their they're to to very of some growth self-administer trial about is population, publications for compliance get compliance and older enroll or years low take the for the willing an agree, of there's down own

Elemer Piros

analysis to just John, performed. on GeNeSIS And up follow set, data that the the you

the in population result, severe velocity, same be true respond so come the robustly of their that moderate more Isn't that of So so year, patients the also year to and very height, at per would to end growth a appears X.X there perhaps. more end centimeter end the sort the speak, normalized it is be to there would they similar? –

John McKew

no of months after There's you the moderate very And true. difference see statistical height group. can XX treatment. between the that's and in the severe Yes, values SDS that group

So really, the faster, further as XX moderate the group starts in then and months, the about group. behind, after place they grow severe they're same

peers progressing a different So even at rate, in growing the though their at is to same the group relation they're moderate both rate.

Elemer Piros

guys. for Okay. Thanks picking me,

Operator

showing I'm to for remarks. you. closing questions time. the in this call over Thank no hand I'll back at further queue Mr. the Hawkins

Rick Hawkins

interest, to much. Thank conferences your year. coming you this very with investors everyone. month the at other we for speaking you venues thank look forward And in the Well, investment Okay. and

Operator

conference Ladies and concludes this gentlemen, call. today's

now may You disconnect.

Lumos Pharma (LUMO) 10 Mar 212020 Q4 Earnings call transcript